SPSathya Narayanan Patmanathan

Sathya Narayanan Patmanathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sathya Narayanan Patmanathan has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Myo-Inositol Moderates Glucose-Induced Effects on Human Placental 13C-Arachidonic Acid Metabolism

    by Oliver C. Watkins, Victoria K. B. Cracknell-Hazra, Reshma Appukuttan Pillai, Preben Selvam, Hannah E. J. Yong, Neha Sharma, Sathya Narayanan Patmanathan, Amaury Cazenave-Gassiot, Anne K. Bendt, Keith M. Godfrey, et al.

    Maternal hyperglycemia is associated with disrupted transplacental arachidonic acid (AA) supply and eicosanoid synthesis, which contribute to adverse pregnancy outcomes. Since placental inositol is lowered with increasing glycemia, and since myo-inositol appears a promising intervention for gestational diabetes, we hypothesized that myo-inositol might rectify glucose-induced perturbations in placental AA metabolism. Term placental explants (n = 19) from women who underwent a mid-gestation oral glucose-tolerance-test were cultured with 13C-AA for 48 h in media containing glucose (5, 10 or 17 mM) and myo-inositol (0.3 or 60 µM). Newly synthesized 13C-AA-lipids were quantified by liquid-chromatography-mass-spectrometry. Increasing maternal fasting glycemia was associated with decreased proportions of 13C-AA-phosphatidyl-ethanolamines (PE, PE-P), but increased proportions of 13C-AA-triacylglycerides (TGs) relative to total placental 13C-AA lipids. This suggests altered placental AA compartmentalization towards storage and away from pools utilized for eicosanoid production and fetal AA supply. Compared to controls (5 mM glucose), 10 mM glucose treatment decreased the amount of four 13C-AA-phospholipids and eleven 13C-AA-TGs, whilst 17 mM glucose increased 13C-AA-PC-40:8 and 13C-AA-LPC. Glucose-induced alterations in all 13C-AA lipids (except PE-P-38:4) were attenuated by concurrent 60 µM myo-inositol treatment. Myo-inositol therefore rectifies some glucose-induced effects, but further studies are required to determine if maternal myo-inositol supplementation could reduce AA-associated pregnancy complications.


  • A PDZ Protein GIPC3 Positively Modulates Hedgehog Signaling and Melanoma Growth

    by Sathya Narayanan Patmanathan, Bing Teck Tong, Jia Hao Jackie Teo, Yong Zheng Jonathan Ting, Nguan Soon Tan, Siew Hoon Kenice Sim, Yng-Cun Ta, Wei-Meng Woo


  • CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective

    by Sathya Narayanan Patmanathan, Nareshwaran Gnanasegaran, Moon Nian Lim, Roslina Husaini, Kamal Shaik Fakiruddin, Zubaidah Zakaria

    The clustered regularly interspaced short palindromic repeats-associated protein 9 or CRISPR/Cas9 system is one of the hottest topics discussed lately due to its robustness and effectiveness in genome editing. The technology has been widely used in life science research including microbial, plant, animal, and human cell studies. Combined with the pluripotency of stem cells, the technology represents a powerful tool to generate various cell types for disease modeling, drug screening, toxicology, and targeted therapies. Generally, the CRISPR/Cas9 system has been applied in genetic modification of pluripotent or multipotent stem cells, after which the cells are differentiated into specific cell types and used for functional analysis or even clinical transplantation. Recent advancement in CRISPR/Cas9 technology has widened the scope of stem cell research and its therapeutic application. This review provides an overview of the current application and the prospect of CRISPR/Cas9 technology, particularly in stem cell research and therapy.


  • Mechanisms of sphingosine 1-phosphate receptor signalling in cancer

    by Sathya Narayanan Patmanathan, Wei Wang, Lee Fah Yap, Deron R. Herr, Ian C. Paterson


  • Open Access

    HOPX functions as a tumour suppressor in head and neck cancer

    by Lee Fah Yap, Sook Ling Lai, Sathya Narayanan Patmanathan, Ravindran Gokulan, C. Max Robinson, Joe B. White, San Jiun Chai, Pathmanathan Rajadurai, Narayanan Prepageran, Yew Toong Liew, et al.

    Head and neck squamous cell carcinoma (HNSCC) is generalized term that encompasses a diverse group of cancers that includes tumours of the oral cavity (OSCC), oropharynx (OPSCC) and nasopharynx (NPC). Genetic alterations that are common to all HNSCC types are likely to be important for squamous carcinogenesis. In this study, we have investigated the role of the homeodomain-only homeobox gene, HOPX, in the pathogenesis of HNSCC. We show that HOPX mRNA levels are reduced in OSCC and NPC cell lines and tissues and there is a general reduction of HOPX protein expression in these tumours and OPSCCs. HOPX promoter methylation was observed in a subset of HNSCCs and was associated with a worse overall survival in HPV negative tumours. RNAseq analysis of OSCC cells transfected with HOPX revealed a widespread deregulation of the transcription of genes related to epithelial homeostasis and ectopic over-expression of HOPX in OSCC and NPC cells inhibited cell proliferation, plating efficiency and migration, and enhanced sensitivity to UVA-induced apoptosis. Our results demonstrate that HOPX functions as a tumour suppressor in HNSCC and suggest a central role for HOPX in suppressing epithelial carcinogenesis.


  • Open Access

    Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2

    by Sathya Narayanan Patmanathan, Steven P. Johnson, Sook Ling Lai, Suthashini Panja Bernam, Victor Lopes, Wenbin Wei, Maha Hafez Ibrahim, Federico Torta, Pradeep Narayanaswamy, Markus R. Wenk, et al.

    Oral squamous cell carcinoma (OSCC) is a lethal disease with a 5-year mortality rate of around 50%. Molecular targeted therapies are not in routine use and novel therapeutic targets are required. Our previous microarray data indicated sphingosine 1-phosphate (S1P) metabolism and signalling was deregulated in OSCC. In this study, we have investigated the contribution of S1P signalling to the pathogenesis of OSCC. We show that the expression of the two major enzymes that regulate S1P levels were altered in OSCC: SPHK1 was significantly upregulated in OSCC tissues compared to normal oral mucosa and low levels of SGPL1 mRNA correlated with a worse overall survival. Inin vitrostudies, S1P enhanced the migration/invasion of OSCC cells and attenuated cisplatin-induced death. We also demonstrate that S1P receptor expression is deregulated in primary OSCCs and that S1PR2 is over-expressed in a subset of tumours, which in part mediates S1P-induced migration of OSCC cells. Lastly, we demonstrate that FTY720 induced significantly more apoptosis in OSCC cells compared to non-malignant cells and that FTY720 acted synergistically with cisplatin to induce cell death. Taken together, our data show that S1P signalling promotes tumour aggressiveness in OSCC and identify S1P signalling as a potential therapeutic target.


  • Open Access

    The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod

    by Sathya Narayanan Patmanathan, Lee Fah Yap, Paul G. Murray, Ian C. Paterson

    Almost all drugs approved for use in humans possess potentially beneficial ‘off‐target’ effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re‐purposing FTY720 (also known as fingolimod, Gilenya™), an immunomodulatory drug recently approved for the treatment of multiple sclerosis (MS). The therapeutic benefit of FTY720 in MS is largely attributed to the immunosuppressive effects that result from its modulation of sphingosine 1‐phosphate receptor signalling. However, this drug has also been shown to inhibit other cancer‐associated signal transduction pathways in part because of its structural similarity to sphingosine, and consequently shows efficacy as an anti‐cancer agent both in vitro and in vivo. Here, we review the effects of FTY720 on signal transduction pathways and cancer‐related cellular processes, and discuss its potential use as an anti‐cancer drug.


  • Identification of novel small molecule TGF-β antagonists using structure-based drug design

    by Hao Wang, Richard B. Sessions, Stephen S. Prime, Deborah K. Shoemark, Shelley J. Allen, Wei Hong, Sathya Narayanan, Ian C. Paterson

    Aberrant transforming growth factor-β (TGF-β) signalling has been associated with a number of disease pathologies, such as the development of fibrosis in the heart, lung and liver, cardiovascular disease and cancer, hence the TGF-β pathway represents a promising target for a variety of diseases. However, highly specific ways to inhibit TGF-β signalling need to be developed to prevent cross-talk with related receptors and minimise unwanted side effects. We have used used virtual screening and molecular docking to identify small molecule inhibitors of TGF-β binding to TßRII. The crystal structure of TGF-β3 in complex with the extracellular domain of the type II TGF-β receptor was taken as a starting point for molecular docking and we developed a structure-based pharmacophore model to identify compounds that competitively inhibit the binding of TGF-β to TβRII and antogonize TGF-β signalling. We have experimentally tested 67 molecules suggested by in silico screening and similarity searching for their ability to inhibit TGF-β signalling in TGF-β-dependent luciferase assays in vitro and the molecule with the strongest inhibition had an IC50 of 18 μM. These compounds were selected to bind to the SS1 subsite (composed of F30, C31, D32, I50, T51 S52, I53, C54 and E55) of TßRII and all share the general property of being aromatic and fairly flat. Molecular dynamics simulations confirmed that this was the most likely binding mode. The computational methods used and the hits identified in this study provide an excellent guide to medicinal chemistry efforts to design tighter binding molecules to disrupt the TGF-β/TßRII interaction.


  • Association between inflammatory bowel disease gene 5 (IBD5) and interleukin‐23 receptor (IL23R) genetic polymorphisms in Malaysian patients with Crohn's disease

    by Kek Heng Chua, Ida Hilmi, Lay Hoong Lian, Sathya Narayanan Patmanathan, See Ziau Hoe, Way Seah Lee, Khean Lee Goh

    OBJECTIVE:  This study was aimed to investigate the possible association of Crohn's disease (CD) with inflammatory bowel disease gene 5 (IBD5) IGR2198a_1 (rs11739135), IGR2096a_1 (rs12521868) and interleukin‐23 receptor (IL23R) genetic variant (rs1004819) in the Malaysian population.METHODS:  Blood samples from 80 CD patients and 100 healthy controls were recruited. Genomic DNA was extracted and analyzed by polymerase chain reaction‐restriction fragment length polymorphism.RESULTS:  The results revealed that there was an increased frequency of IGR2198a_1 C allele (8.8% in CD, 1.5% in controls, P < 0.05, OR 6.30, 95% CI 1.77–22.31) and IGR2096a_1 T allele (6.9% in CD, 1.5% in controls, P < 0.05, OR 4.85, 95% CI 1.33–17.69) in the CD patients as compared to the controls, suggesting the two variants were potential risk factors of CD. Both risk alleles (C and T) were highest in Indians. In contrast, no significant difference was observed for the IL23R gene variant (rs1004819) between these two groups (P = 0.941). All genotypes and alleles of this gene variant were present in equal ratios in the CD and control groups (OR 1.02, 95% CI 0.66–1.57 for T allele and OR 0.98, 95% CI 0.64–1.52 for C allele).CONCLUSIONS:  There is a strong association between both IBD5 locus variants but not the IL23R gene variant with CD in the Malaysian population. The IBD5 locus variants were highest in Indians, which may explain the increased susceptibility of this particular ethnic group to the disease.